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An economic sub-study was run alongside a large multi-centre randomised trial (MRC-CR06) comparing three chemotherapy
regimens; de Gramont, Lokich and raltitrexed in patients with metastatic colorectal cancer. Patients in six of 45 centres in the
main trial were approached to take part in the sub-study. Chemotherapy delivery costs were assessed in each sub-study
centre with external validity veriﬁed by questionnaire to all other centres. Patient representativeness was assessed. Stochastic
resource use data, including patient borne costs and non-hospital health service resource use were monitored prospectively.
Mean total societal costs were de Gramont=£5051 (s.d. £1910), raltitrexed=£2616 (s.d. £991) and Lokich=£2576 (s.d.
£1711). In pairwise comparisons, statistically signiﬁcant mean total cost differences were shown for de Gramont vs Lokich
(mean difference=£2475, 95%CI £914–£4037, P50.01) and for de Gramont vs raltitrexed (mean difference=£2435, 95%CI
£922–£2948, P50.01). Sensitivity analyses showed little effect on overall costs. The main trial showed de Gramont and
Lokich to be equally effective in terms of survival, quality of life and response rates but Lokich had higher toxicity and hand-
foot syndrome. Raltitrexed showed similar response rates and overall survival but increased toxicity and inferior quality of life
making it a clinically inferior regimen despite its ease of administration and costs. For a comparable clinical outcome, Lokich
can be administered for approximately half the cost of de Gramont.
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Colorectal cancer kills about 20000 people each year in the UK.
Once the disease has spread beyond the limits of surgical cure,
the aim of treatment is to improve quality of life and survival.
In a meta analysis of randomised controlled trials, chemotherapy
has been shown to improve median survival from 8 to 11.7 months
(Colorectal Cancer Collaborative Group, 2000).
A large nation-wide multi-centre randomised trial (MRC-CR06)
has been undertaken to compare three chemotherapy treatments
for patients with advanced colorectal cancer: de Gramont bolus
and infusion 5FU plus folinic acid, Lokich Protracted Venous Infu-
sion 5FU, and raltitrexed (Tomudex
TM) (Maughan et al, 2002).
There is, however, a growing awareness that health care resources
are scarce and therefore as well as assessing comparative effective-
ness in terms of clinical outcomes it is also important to consider
at what cost these outcomes are achieved. In addition to the direct
costs of chemotherapy delivery, regimens can differ in terms of
indirect costs, for example the treatment of serious adverse events
or in travel and other costs borne by patients and their carers.
An economic sub-study using a societal perspective was run
alongside the clinical trial. A cost effectiveness analysis of the three
regimens would have required speciﬁcation of a single outcome as
reﬂecting the objective of the treatments. Within CR06 a number
of outcomes were assessed including overall survival, progression
free survival, response rate, treatment related deaths, toxicity, and
quality of life using EORTC-QLQ C30, HADS and trial speciﬁc
questions. As cost effectiveness analyses cannot handle programmes
with multiple objectives (Drummond et al, 1997) we here report
relative costs and consequences of the three regimens over the
initial 12 week period.
MATERIALS AND METHODS
Details of the design of the main trial are available elsewhere
(Maughan et al, 2002). Brieﬂy, 905 patients with advanced meta-
static colorectal carcinoma for whom palliative chemotherapy was
the only remaining active treatment option, were randomised to
receive de Gramont (dl-folinic acid 100 mg m
72, 5-ﬂuorouracil
(5FU) bolus 400 mg m
72 and infusion 600 mg m
72 day 1 and
2, q14d), Lokich (protracted venous infusion of 5FU
300 mg m
72 day
71) or raltitrexed (3 mg m
72 i.v. q21d) for an
initial period of 12 weeks.
The economic study was undertaken on a sub-sample of patients
from six of the 45 centres taking part in the main trial, selected to
represent a geographical spread across the UK. Each centre
provided all three chemotherapy regimens. Study patients in the
main trial who were receiving treatment in these six centres were
invited to participate in the economic sub-study via separate
informed consent.
Costs of delivering chemotherapy were estimated via a detailed
costing exercise undertaken in each centre in the sub-study. To
verify representativeness, a questionnaire on methods of delivering
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www.bjcancer.comchemotherapy was posted to research nurses and pharmacists in all
other centres participating in the main trial. Representativeness of
patients in the economics sub-study was assessed by comparing
demographic and other characteristics of sub-study patients with
all patients in the main trial.
Costing methods
Costing was undertaken from a societal perspective in which all
costs were considered regardless of who bore them. Stochastic
resource data (i.e. which were expected to vary by patient) were
collected prospectively over the 12 week period following randomi-
sation. A research nurse in each of the six centres monitored
patient notes for investigations undertaken and all additional treat-
ments received. Patient borne costs were recorded in diaries by
patients, or where necessary by a relative. Weekly entries were
made listing all costs incurred by patients and their families,
including travel and time taken off work by others to care for
the patient. Use of non-hospital health and social care resources
(general practitioner, district nurse and other health or social
service) were also recorded in the diaries.
Monetary valuation of resource use was undertaken by attaching
unit costs to recorded quantity data. All costs are in 1998/99 prices.
In the case of all chemotherapy drugs, costs have been calculated
on the assumption that any drug remaining in partly used vials will
be discarded. Unit costs for drugs are from the British National
Formulary (British National Formulary, 1998) which do not reﬂect
any bulk purchase discounts which may be negotiated. Cost of GP
and district nurse visits are from Netten et al (1998). Costs of in-
patient stays, investigations, materials and disposables were
provided by the Finance department of one of the participating
centres. The opportunity cost of time taken off work by carers
was on the basis of average hourly wages (Ofﬁce for National
Statistics, 1999). Robustness of results were assessed via a series
of one-way sensitivity analyses. Total societal costs were assessed
against outcome data from the whole trial population on survival
and quality of life.
Statistical methods
Independent samples t-tests (a=0.05) were used to test for differences
in mean costs in pairwise comparisons of the three regimens.
Representativeness of the sub-sample was assessed by comparing
demographic and other characteristics with all other CR06 patients
using w
2. Details of the statistical methods used on clinical outcome
data are available elsewhere (Maughan et al, 2002).
RESULTS
Representativeness of sub-sample patients
A sub-sample of 68 patients was obtained. There do not appear to
be any differences between this sub-sample and all other patients in
the trial as shown in Table 1.
The survival pattern of patients in the economics sub-study was
similar to that of those not included (hazard ratio=0.97, 95%CI
0.74–1.27, P=0.81). In terms of serious adverse events, patients
in the economics sub-study were generally representative of the
whole, and although no fatal or life threatening chemotherapy
related events occurred, a higher than expected proportion of
patients required hospitalisation.
Representativeness of methods of chemotherapy delivery in
sub-study centres
After one reminder, a response rate of 90% was achieved for the
pharmacist questionnaire and 95% for the research nurse question-
naire in centres which did not participate in the sub-study.
Table 2 compares sub-study with other centres. This was a prag-
matic trial and during the study period some centres began to
provide de Gramont to some patients on an out-patient basis.
The proportion of sub-study centres which provided de Gramont
on an out patient basis was broadly similar to the other centres
(two of six in the sub-study vs nine of 35 in the other centres
who reported). Table 2 also shows sub-study centres to be broadly
representative in terms of a number of other variables.
Mean total societal costs
Mean total societal costs were highest for de Gramont (£5051,
s.d.=1910), followed by raltitrexed (£2616, s.d.=991) and Lokich
(£2576, s.d.=1711) as shown in Table 3. Costs were based on the
assumption that all patients in the Lokich arm, and all who
received de Gramont as out-patients, used Hickman, rather than
other central venous access devices.
With regard to de Gramont, the costs shown reﬂect the way that
chemotherapy was actually delivered within the trial i.e. with a mix
of in-patient (63%) and out-patient (37%) treatment. Cost of
chemotherapy drugs (£1046) represented 39% of the cost of de
Gramont delivery (£2672) which in turn made up 53% of total
societal costs (£5051). In-patient admissions other than for
chemotherapy (£1274) represented a further 25% of total societal
costs with patient borne costs (£914) representing 18%.
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Table 1 Comparison of sub-sample with other CR06 patients
CR06 patients not participating CR06 patients participating
in the sub-study (%) in the sub-study (%) w
2 (P value)
Gender:
male 552 (65.9) 47 (69.1) 0.158, d.f.=1 (P=0.69)
female 285 (34.1) 21 (30.9)
Age:
555 193 (23.1) 14 (20.6) 3.455, d.f.=2 (P=0.18)
55–64 289 (34.5) 31 (45.6)
65+ 355 (42.4) 23 (33.8)
Performance status:
PS 0 276 (33.0) 24 (35.3) 0.316, d.f.=2 (P=0.85)
PS 1 374 (44.7) 28 (41.2)
PS 2 187 (22.3) 16 (23.5)
Regimen:
de Gramont 286 (34.2) 17 (25.0) 2.590, d.f.=2 (P=0.27)
Lokich 277 (33.1) 24 (35.3)
Raltitrexed 274 (32.7) 27 (39.7)
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(11), 1684–1690In the case of Lokich, cost of chemotherapy drugs (£433)
represented 44% of the cost of chemotherapy delivery (£983)
which in turn represented 38% of total societal costs (£2576).
In-patient admissions (£400) were responsible for a further 16%
of total societal costs with patient borne costs (£762) representing
30%.
By contrast, the cost of raltitrexed drugs (£1260) represented
almost the whole (97%) of chemotherapy delivery (£1305) which
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Table 2 Comparison of chemotherapy delivery: sub-sample vs all other centres
Six centres in sub-sample Other centres in CR06 trial
Method Lokich de Gramont Raltitrexed Lokich de Gramont Raltitrexed
Chemotherapy
in-patient 1 23
out-patient 2 6 9 39
both 3 3
Hospital buys and ﬁlls pump 5 31
Contractor supplies pump 1 6
Chemotherapy administered by nurse only nurse only nurse only nurse 38
doctor 1
nurse 36
doctor 2
nurse 38
doctor 1
Grade range D–H D–H D–H E–H D–G E–G
Pump changed
at hospital 4 5 33 15
at home 1 4
both 2 2
Anaesthetic
(Hickman line insertion)
local 4
general 0
both 2
local 27
general 8
both 3
Inserted by anaesth. 3
radiol. 2
consult. 2
sp. nurse 1
anaesth. 5
radiol. 12
consult. 10
sp. nurse 5
other 6
Time taken 20–60 min 15–60 min
Table 3 Mean cost (£) of individual cost elements. All regimens
Mean units and unit costs by regimen Mean total cost by regimen
de Gramont Lokich Raltitrexed
de Gramont Lokich Raltitrexed
Resource variable
Units
(s.d.)
Unit cost
(£) (s.d.)
Units
(s.d.)
Unit cost
(£) (s.d.) Units
Unit cost
(£)
Total cost
(£) (s.d.)
Total cost
(£) (s.d.)
Total cost
(£) (s.d.)
Chemotherapy delivery
chemotherapy drugs (a) 6 174 12 36 4 315 1046 (419.9) 433 (131.5) 1260 (376.2)
pharmacy staff* 60 113 31
nursing (b) 2 12 2.7 12 1.2 12 25 32 14
use of pump 67 178 0
Hickman line 85 (113.7) 227 (0) 0 (0)
in patient costs (c) 6 (5.5) 231 0 (0) 231 0 (0) 231 1389 (1264.8) 0 (0) 0 (0)
Total 2672 983 1305
Other hospital
prescribed drugs* 142 (140) 48 (55.7) 73 (73.5)
investigations* 283 (135.8) 218 (125.7) 295 (131.7)
admissions (c) 8 (14) 231 2 (2.7) 231 2 (3.4) 231 1274 (2354.3) 400 (634.7) 446 (787.1)
Total 1699 666 814
Primary care costs
GP home visits (d) 2 (3.6) 39 4 (10.6) 39 1 (1.8) 39 76 (139.7) 54 (114.8) 51 (70.3)
GP surgery visits (d) 1 (1.3) 13 1 (1.4) 13 1 (1.8) 13 9 (17.4) 12 (18.4) 15 (23.0)
district nurse (b) 2.6 (2) 41 4 (5.7) 41 1 (1.4) 41 108 (81.2) 155 (231.9) 31 (55.9)
specialist nurse (b) 0.5 (0.9) 41 1 (2.8) 41 1 (2.4) 41 20 (35.6) 41 (115.7) 55 (97.6)
Total 114 126 152
Patient borne costs
by patient 276 (239.8) 261 (200.2) 93 (63.6)
by carer (b) 56 (111.3) 11.45 44 (113) 11.45 27 (62.9) 11.45 638 (1274.6) 501 (1294.1) 311 (719.8)
Total 914 762 404
Total societal costs 5051 (1910) 2576 (1711) 2616 (991)
(a)=sessions, (b)=hours, (c)=days, (d)=visits. *Unit costs cannot be shown because of mix of different pharmacy staff/drugs/investigations.
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admissions (£446) represented a further 17% with patient borne
costs (£404) lower than the other regimens and representing 15%.
Differences in total costs and individual cost elements
Total societal costs are made up of 15 individual cost elements.
Mean differences and conﬁdence intervals for those variables where
these differences were statistically signiﬁcant (pairwise compari-
sons) are given in Table 4a (de Gramont vs Lokich) Table 4b
(de Gramont vs raltitrexed) and Table 4c (Lokich vs raltitrexed).
Differences in mean total societal costs between de Gramont and
Lokich (£2475) were statistically signiﬁcant (P50.01) as were those
between de Gramont and raltitrexed (£2435, P50.01). Total costs
of Lokich and raltitrexed were similar with a mean difference of
only £40.
Examination of differences in the mean estimates for each
element speciﬁes where the differences in total costs occur.
Although there were no signiﬁcant differences in total societal costs
between Lokich and raltitrexed, pairwise comparisons showed
statistically signiﬁcant differences in the cost of chemotherapy
drugs (raltitrexed higher, P50.001), pharmacy staff (Lokich higher,
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Table 4a Mean differences of individual cost variables achieving statistical signiﬁcance (£):
de Gramont vs Lokich
Regimen
Resource variable de Gramont Lokich Mean difference 95% CI P value
Chemotherapy delivery
chemotherapy drugs 1046 433 613 384, 843 50.001
pharmacy staff 60 113 753 792, 714 0.01
nursing 25 32 78 711, 74 50.001
use of pump 67 178 7111 7159, 764 50.001
Hickman line 85 227 7142 7203, 782 50.001
in patient costs 1389 0 1389 715, 2063 0.001
Other hospital costs
prescribed drugs 142 48 94 17, 172 0.02
Total societal costs 5051 2576 2475 914, 4037 0.003
Table 4b Mean differences of individual cost variables achieving statistical signiﬁcance (£):
de Gramont vs raltitrexed
Regimen
Resource variable de Gramont Raltitrexed Mean difference 95% CI P value
Chemotherapy delivery
pharmacy staff 60 31 29 12, 46 0.003
nursing 25 14 11 8, 15 50.001
use of pump 67 0 67 19, 114 0.009
Hickman line 85 0 85 25, 146 0.009
in patient costs 1389 0 1389 715, 2063 0.001
Primary care costs
district nurse 108 31 77 24, 130 0.006
Total societal costs 5051 2616 2435 922, 3948 0.005
Table 4c Mean differences of individual cost variables achieving statistical signiﬁcance (£):
Lokich vs raltitrexed
Regimen
Resource variable Lokich Raltitrexed Mean difference 95% CI P value
Chemotherapy delivery
chemotherapy drugs 433 1260 7827 7992, 7662 50.001
pharmacy staff 113 31 82 46, 119 50.001
nursing 32 14 19 17, 20 50.001
use of pump 178 0 178 * *
Hickman line 227 0 227 * *
Primary care costs
district nurse 155 31 124 10, 238 0.034
Patient borne costs
by patient 261 93 169 69, 268 0.002
Total societal costs 2576 2616 40 71059, 979 n.s.
*=cannot be computed because standard deviations of both groups=0.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(11), 1684–1690P50.001), hospital nurses (Lokich higher, P50.001), district
nurses (Lokich higher, P50.05) and patient borne costs excluding
carers (Lokich higher P50.01).
Outcomes
Full clinical results are available elsewhere (Maughan et al, 2002) and
are summarised in Table 5. The three regimens were broadly equiva-
lent in terms of overall survival and response but there were higher
treatment-related deaths in the raltitrexed arm (18 out of 301 vs 3
out of 604).
De Gramont and Lokich were broadly equivalent in terms of
quality of life, although Lokich patients reported more soreness
of the hands and feet. Raltitrexed was inferior to de Gramont in
terms of palliation (lack of appetite), role functioning, social func-
tioning and global quality of life. Raltitrexed was also inferior to
Lokich in terms of palliation, fatigue, appetite, nausea/vomiting,
constipation and emotional functioning.
Sensitivity analyses
A number of factors were identiﬁed that could have implications
for the cost of the different chemotherapy regimens. As Table 2
indicates, nurses within the grade range D to H could be respon-
sible for the administration of chemotherapy. The base case
analysis assumed the mid point of this range and therefore used
the cost of an F grade nurse. It is important, however, to consider
the potential impact of either extreme grade of nurse being used to
carry out this activity.
Another important difference is the two possible methods of
delivery of the de Gramont regimen. The base case analysis calcu-
lated the cost of the de Gramont regimen based on a mixture of in-
patient and out-patient delivery. There are clearly cost implications
if this regimen is always provided on an in-patient or always
provided on an out-patient basis.
By the end of the study period, many centres had changed from
using Hickman lines in the delivery of the Lokich regimen, to
cheaper peripherally implanted central catheters. The impact of this
change needs also to be considered.
In the base case analysis, the costs of in-patient stays, investiga-
tions, materials and disposables were provided by the Finance
Department of one of the participating centres. To take account
of possible variations in these ﬁgures, the analysis was repeated
twice more using extreme values; once assuming that costs were
half those in the base case analysis and once assuming they were
double.
One ﬁnal factor worth considering is the impact on nursing
time of patients receiving the Lokich regimen being trained to
change the pump themselves rather than attending hospital for a
nurse to change it.
Tables 6a–c show the impact of the above changes on the mean
total societal costs for each of the pairwise comparisons. The over-
all results are not altered by any of these changes, with the
exception of providing de Gramont solely on an out-patient basis.
The differences in total societal costs of providing de Gramont as
an out-patient and as an in-patient, may not appear as great as
may have been expected. This is likely to be due to the small
numbers being considered here. Altering the size of the cost esti-
mates, whilst not effecting the overall results, did have a different
impact on the three regimens. When using double cost estimates,
the total societal cost of Lokich is higher than that of raltitrexed,
although this difference is not statistically signiﬁcant.
DISCUSSION
Costs
This study has demonstrated that over a 12 week period, study
patients who received the de Gramont regimen had signiﬁcantly
higher costs in terms of both direct chemotherapy delivery and
total societal costs than those receiving either Lokich or raltitrexed.
New drugs usually carry a high drug cost but this study has
shown that despite the relatively high cost of raltitrexed, overall
societal costs compare favourably with those of the other regimens.
This is consistent with Ross et al (1996) who also found the total
cost of raltitrexed to be comparable to that of continuously admi-
nistered 5FU and lower than that of de Gramont. Moreover, the
lower frequency of attendance associated with the raltitrexed 3
weekly regimen also results in lower patient borne costs. The
frequency of chemotherapy delivery also affects the mean costs of
both pharmacy and nursing staff. This is in line with the results
from other studies which found pharmacy staff costs to be lower
for raltitrexed than for other 5FU regimens (Summerhayes et al,
1997).
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Table 5 Comparison of outcomes for the three regimens
de Gramont vs Lokich de Gramont vs Raltitrexed Lokich vs Raltitrexed
Overall survival HR 1.13 P=0.17 HR 1.01 P=0.94 HR 0.89 P=0.22
Progression-free survival HR 1.01 P=0.92 HR 0.85 P=0.06 HR 0.84 P=0.05
Response rate 23% vs 25% P=0.85 23% vs 18% P=0.20 25% vs 18% P=0.12
Treatment-related deaths 1 vs 2 P=1.00 1 vs 18 P=0.0002 2 vs 18 P=0.0006
Toxicity Lokich worse:
Stomatitis
Raltitrexed worse:
Diarrhoea
Lethargy
Raltitrexed worse:
Nausea
Anorexia
de Gramont worse:
Neutropenia
White cell count
Neutropenia
Platelets
Diarrhoea
Lethargy
Platelets
Neutropenia
Quality of life Lokich worse:
Pain
Problems eating
Hands/feet
Raltitrexed worse:
Palliation
Appetite
Emotional functioning
Raltitrexed worse:
Palliation
Fatigue
Appetite
Nausea/vomiting
de Gramont worse:
Diarrhoea
Hands/feet
Constipation
Emotional functioning
Lokich worse:
Problems eating
Hands/feet
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British Journal of Cancer (2002) 86(11), 1684–1690 ã 2002 Cancer Research UKFrom the hospital perspective the Lokich regimen is the least
costly. Although raltitrexed had the lowest costs in terms of phar-
macy and nursing time, these were not sufﬁcient to offset the
higher drug costs. This study thus provides no evidence to support
the results of Kerr and O’Connor (1997) which showed that ralti-
trexed reduces chemotherapy costs when compared with the
Lokich regimen.
As regards the cost of treating chemotherapy related side effects,
no signiﬁcant differences were found in terms of prescribed drugs.
This is in contrast to the ﬁnding of Elliott (1996) where drug costs
for management of side effects were lower for raltitrexed patients as
compared with those receiving 5FU plus folinic acid. While the
present study showed a trend toward higher in-patient costs for
de Gramont (other than to receive chemotherapy) these differences
did not reach statistical signiﬁcance (de Gramont vs Lokich, mean
difference=£874, P=0.181, de Gramont vs raltitrexed, mean differ-
ence=£828, P=0.206), although this must be considered in the
light of the small sample size. General practitioner visits, either
at home or in the surgery, were also similar suggesting that patients
on one regimen are not seeking more help in primary care than
patients on any other regimen. Overall, this study provided no
evidence that the cost implications of side effects and serious
adverse events (requiring prescribed medication or hospital admis-
sion) differ between regimens.
Potential for cost improvement
Clearly, these reported costs can vary by changing the way in
which chemotherapy is delivered. For example, providing de
Gramont on an out-patient basis avoids in-patient costs and
can thus signiﬁcantly reduce hospital costs. Within this study
patients who received de Gramont as out-patients (n=6) had
chemotherapy delivery costs which were roughly 50% lower
(P=0.011) than for in-patient delivery. The relatively low degree
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Table 6a Sensitivity analyses: de Gramont vs Lokich
Regimen
Sensitivity analysis de Gramont Lokich Mean difference 95% CI P value
Chemotherapy administered by D grade nurse 5046 2569 2477 915, 4038 0.003
Chemotherapy administered by H grade nurse 5058 2585 2473 911, 4035 0.003
All de Gramont as out-patient 4961 2576 2385 764, 4835 0.056
All de Gramont as in-patient 5096 2576 2520 758, 4282 0.007
PICC line 5000 2424 2576 1013, 4139 0.002
Patients trained to change pump themselves 5051 2565 2486 925, 4047 0.003
Costs of in-patient stays, investigations,
materials and disposables, half of original
3796 2049 1748 322, 3173 0.019
Costs of in-patient stays, investigations,
materials and disposables, double original
7560 3630 3930 1904, 5956 0.001
Table 6b Sensitivity analyses: de Gramont vs raltitrexed
Regimen
Sensitivity analysis de Gramont Raltitrexed Mean difference 95% CI P value
Chemotherapy administered by D grade nurse 5046 2613 2433 920, 3946 0.005
Chemotherapy administered by H grade nurse 5058 2620 2439 926, 3952 0.005
All de Gramont as out-patient 4961 2616 2346 73608, 8299 0.242
All de Gramont as in-patient 5096 2616 2480 565, 4395 0.019
PICC line 5000 2616 2385 869, 3901 0.006
Patients trained to change pump themselves 5051 2616 2435 922, 3948 0.005
Costs of in-patient stays, investigations,
materials and disposables, half of original
3796 2294 1503 289, 2716 0.020
Costs of in-patient stays, investigations,
materials and disposables, double original
7560 3260 4300 1993, 6607 0.002
Table 6c Sensitivity analyses: Lokich vs raltitrexed
Regimen
Sensitivity analysis Lokich Raltitrexed Mean difference 95% CI P value
Chemotherapy administered by D grade nurse 2569 2613 744 71062, 975 0.931
Chemotherapy administered by H grade nurse 2585 2620 734 71053, 984 0.946
All de Gramont as out-patient 2576 2616 740 71059, 979 0.937
All de Gramont as in-patient 2576 2616 740 71059, 979 0.937
PICC line 2424 2616 7192 71210, 827 0.703
Patients trained to change pump themselves 2565 2616 751 71069, 968 0.919
Costs of in-patient stays, investigations,
materials and disposables, half of original
2049 2294 7245 71241, 751 0.619
Costs of in-patient stays, investigations,
materials and disposables, double original
3630 3260 370 7812, 1552 0.527
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(11), 1684–1690of statistical signiﬁcance is likely to be due to the small numbers
involved. Chemotherapy delivery, however, only represents a part
of total societal costs and de Gramont patients receiving out-
patient delivery had higher primary care costs than those receiv-
ing it as in-patient (£283 vs £85, P=0.04). Even on the basis of
these very small numbers, use of de Gramont as an out-patient
regimen is likely to have important implications for hospital
costs.
There is also the possibility of further reducing de Gramont
drug costs by modifying the dose. In an ongoing MRC trial
(CR08) the de Gramont regimen has been modiﬁed to
200 mg m
72 folinic acid plus 400 mg m
72 5FU bolus on day 1
followed by 2800 mg m
72 5FU infusion over 46 h. Calculating
the cost of the chemotherapy drugs that de Gramont patients in
the present sub-study would have received if they had been given
this modiﬁed regimen shows a signiﬁcant reduction in mean drug
costs from £1046 to £667 during the 12 weeks (P50.001). Deliver-
ing modiﬁed de Gramont on an out-patient basis will have further
implications for hospital costs. Patients who received de Gramont
as an out-patient in the present trial still incurred mean in-patient
costs for chemotherapy delivery, although these were much lower
(£231 vs £2084) than for those who received this regimen as an
in-patient.
CONCLUSION
The toxicity and impaired quality of life observed with raltitrexed
make it a clinically inferior regimen despite its ease of adminis-
tration and costs. In making a choice between de Gramont and
Lokich, a number of issues need to be taken into consideration
given that their overall clinical beneﬁt is equivalent. Lokich is
inferior to de Gramont only in terms of the increased incidence
of minor adverse events and central line complications. There
was no evidence that the management of these events had differ-
ent cost implications between the two regimens. However, hand
and feet soreness, while neither affecting measurable quality of
life nor resulting in costs, can be an added burden, if a manage-
able one. Patients have recorded no difference in terms of
interference with daily living between de Gramont and Lokich.
However, in current practice modiﬁed de Gramont is now
administered as an out-patient regimen in nearly all centres. This
has the positive effect of reducing interference with normal life
and cutting hospital costs, but does mean that all patients now
require central lines with the associated incidence of line
complications.
In conclusion, in comparison with de Gramont as administered
in this study, the signiﬁcant reduction in costs of Lokich with
comparable clinical beneﬁt suggest that it offers the best value
for money of the three regimens.
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